Michael Hubalek
Overview
Explore the profile of Michael Hubalek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
1628
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brunner C, Arvandi M, Marth C, Egle D, Baumgart F, Emmelheinz M, et al.
J Clin Oncol
. 2024 Aug;
43(2):180-188.
PMID: 39163561
Purpose: Medication-related osteonecrosis of the jaw (MRONJ) is one of the most important toxicities of antiresorptive therapy, which is standard practice for patients with breast cancer and bone metastases. However,...
2.
Klocker E, Hasenleithner S, Bartsch R, Gampenrieder S, Egle D, Singer C, et al.
Mol Oncol
. 2024 Jun;
PMID: 38867388
The advancements in the detection and characterization of circulating tumor DNA (ctDNA) have revolutionized precision medicine and are likely to transform standard clinical practice. The non-invasive nature of this approach...
3.
Gampenrieder S, Rinnerthaler G, Tinchon C, Petzer A, Balic M, Heibl S, et al.
Breast Cancer Res
. 2021 Dec;
23(1):112.
PMID: 34906198
Background: About 50% of all primary breast cancers show a low-level expression of HER2 (HER2-low), defined as immunohistochemically 1+ or 2+ and lack of HER2 gene amplification measured by in...
4.
Rinnerthaler G, Gampenrieder S, Petzer A, Hubalek M, Petru E, Sandholzer M, et al.
Ther Adv Med Oncol
. 2021 Oct;
13:17588359211042301.
PMID: 34691243
Background: Bendamustine, a medication approved for the treatment of indolent non-Hodgkin lymphoma, has already shown anticancer activity in metastatic breast cancer (MBC). Here, we present the results of a phase...
5.
Bartsch R, Singer C, Pfeiler G, Hubalek M, Stoeger H, Pichler A, et al.
Br J Cancer
. 2021 Mar;
124(11):1795-1802.
PMID: 33762716
Background: Preoperative chemotherapy containing anthracyclines and taxanes is well established in early-stage breast cancer. Previous studies have suggested that the chemotherapy sequence may matter but definitive evidence is missing. ABCSG...
6.
Singer C, Pfeiler G, Hubalek M, Bartsch R, Stoger H, Pichler A, et al.
Eur J Cancer
. 2020 Apr;
132:43-52.
PMID: 32325419
Background: Immune-based strategies represent a promising approach in breast cancer (BC) treatment. The glycoprotein mucin-1 (MUC-1) is overexpressed in more than 90% of BC patients, and is targeted by the...
7.
Steger G, Egle D, Bartsch R, Pfeiler G, Petru E, Greil R, et al.
Breast
. 2020 Feb;
50:64-70.
PMID: 32062536
Background: STEPAUT, an Austrian non-interventional study, evaluated the safety and efficacy of everolimus plus exemestane in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast...
8.
Fitzal F, Bjelic-Radisic V, Knauer M, Steger G, Hubalek M, Balic M, et al.
Ann Surg
. 2019 May;
269(6):1163-1169.
PMID: 31082916
Background: Conflicting evidence exists regarding the value of surgical resection of the primary in stage IV breast cancer patients. Objective: The prospective randomized phase III ABCSG-28 POSYTIVE trial evaluated median...
9.
Jahn B, Rochau U, Kurzthaler C, Hubalek M, Miksad R, Sroczynski G, et al.
BMC Cancer
. 2017 Oct;
17(1):685.
PMID: 29037213
Background: Due to high survival rates and the relatively small benefit of adjuvant therapy, the application of personalized medicine (PM) through risk stratification is particularly beneficial in early breast cancer...
10.
Oberguggenberger A, Meraner V, Sztankay M, Hilbert A, Hubalek M, Holzner B, et al.
Clin Breast Cancer
. 2017 Oct;
18(1):38-44.
PMID: 29017754
Purpose: Health behavior (HB) has been identified as contributing to breast cancer (BC) disease outcome. The present study was subjected to gain more in-depth insight into breast cancer survivors' (BCS)...